Unraveling the effects of FLASH and conventional irradiation on retinal pigment epithelial cells: in vitro and in vivo studies
- PMID: 40594566
- PMCID: PMC12218338
- DOI: 10.1038/s41598-025-06101-x
Unraveling the effects of FLASH and conventional irradiation on retinal pigment epithelial cells: in vitro and in vivo studies
Abstract
The retinal pigment epithelium (RPE) is a fundamental monolayer of pigmented cells that supports visual function, situated between the neural retina and choroidal blood vessels. Radiotherapy is a common treatment for ocular tumors such as uveal melanoma; however, the RPE is inevitably exposed to radiation during treatment. FLASH radiotherapy, characterized by ultra-high dose-rates, has emerged as a promising approach to minimize normal tissue toxicity while maintaining tumor control. Despite its potential, few preclinical studies have explored the effects of FLASH irradiation on the RPE, and no studies have directly compared FLASH with conventional (CONV) radiotherapy in this context. Using a LINAC capable of switching between FLASH and CONV irradiation, we here address the radiobiological effects on ARPE-19 cells, an in vitro RPE model, and the RPE of living mice. FLASH treatment demonstrated protective effects on ARPE-19 cells, enhancing cell viability and modulating cytokine expression (e.g., IL-6, IL-8). Furthermore, RPE tissue exhibited dose-dependent radiation sensitivity, with FLASH-irradiated mice performing better than CONV-treated ones. These findings indicate that FLASH radiotherapy may protect the RPE during ocular tumor treatment and provide insights into tissue-specific radiation sensitivity in the eye, supporting further research into its clinical applications.
Keywords: FLASH radiotherapy; Linear accelerator (LINAC); Ocular tumors; Radiation-induced toxicity; Retinal pigment epithelium (RPE); Uveal melanoma.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Figures
References
MeSH terms
Substances
Grants and funding
- Allergan contribution to research to ES/Allergan (an AbbVie Company)
- Project no. ECS_00000017; CUP I53C22000780001/EU funding within the Next Generation EU, Piano Nazionale di Ripresa e Resilienza (PNRR), Mission 4, Component 2, Innovation Ecosystems-Tuscany Health Ecosystem (THE), spoke 1 "Advanced Radiotherapies and Diagnostics in Oncology" to MC, G Sansevero, BD, FP, AC, MC, AG, SC, GG. and spoke 8 "Imaging in Neuroscience" to ES, BDM.
- INFN-FRIDA grant to to M C, BD, ES, FDM/INFN-FRIDA
- grant prog.n.134/2021 to CPFR/Fondazione Pisa
- #IG 2024 ID-30434 AIRC project to MC/Fondazione AIRC per la ricerca sul cancro ETS
LinkOut - more resources
Full Text Sources
